Graig Suvannavejh
Stock Analyst at Mizuho
(4.41)
# 345
Out of 5,124 analysts
172
Total ratings
57.36%
Success rate
16.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $3.72 | +34.41% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $40.40 | +33.66% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $159.96 | +21.28% | 2 | Dec 2, 2025 | |
| INSM Insmed | Maintains: Outperform | $196 → $256 | $174.04 | +47.09% | 12 | Dec 1, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $37.42 | +22.93% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $81.88 | +22.13% | 1 | Nov 20, 2025 | |
| IMTX Immatics | Maintains: Outperform | $19 → $23 | $10.50 | +119.05% | 4 | Nov 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $54 → $56 | $67.30 | -16.79% | 7 | Nov 18, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $44 → $46 | $34.57 | +33.06% | 3 | Nov 11, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $200 → $202 | $182.64 | +10.60% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $19 | $25.12 | -24.36% | 11 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.60 | +150.00% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.56 | +5,296.65% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $1.56 | +124.36% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $1.79 | +179.33% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $6.58 | +51.98% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $7.70 | +42.86% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $18.27 | +42.31% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $12.08 | -33.77% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $34.60 | -4.62% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.99 | +281.91% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $8.14 | +809.09% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $5 | $7.57 | -33.95% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $5.84 | -82.88% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $107.04 | -67.30% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $27.96 | -71.39% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $63.54 | -10.29% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $29.81 | -83.23% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $8.86 | +283.75% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $9.36 | +199.15% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $24.82 | +24.92% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $13.08 | +2,805.20% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.78 | +166.85% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $29.04 | +23.97% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $32.68 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $2.90 | +1,175.86% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $170.00 | -24.71% | 1 | Sep 14, 2020 |
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.72
Upside: +34.41%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $40.40
Upside: +33.66%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $159.96
Upside: +21.28%
Insmed
Dec 1, 2025
Maintains: Outperform
Price Target: $196 → $256
Current: $174.04
Upside: +47.09%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $37.42
Upside: +22.93%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $81.88
Upside: +22.13%
Immatics
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $10.50
Upside: +119.05%
Halozyme Therapeutics
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $67.30
Upside: -16.79%
IDEAYA Biosciences
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $34.57
Upside: +33.06%
Axsome Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $182.64
Upside: +10.60%
Nov 3, 2025
Maintains: Neutral
Price Target: $24 → $19
Current: $25.12
Upside: -24.36%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.60
Upside: +150.00%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.56
Upside: +5,296.65%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $1.56
Upside: +124.36%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.79
Upside: +179.33%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $6.58
Upside: +51.98%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $7.70
Upside: +42.86%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $18.27
Upside: +42.31%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $12.08
Upside: -33.77%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $34.60
Upside: -4.62%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.99
Upside: +281.91%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $8.14
Upside: +809.09%
Sep 19, 2024
Downgrades: Neutral
Price Target: $50 → $5
Current: $7.57
Upside: -33.95%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $5.84
Upside: -82.88%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $107.04
Upside: -67.30%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $27.96
Upside: -71.39%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $63.54
Upside: -10.29%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $29.81
Upside: -83.23%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $8.86
Upside: +283.75%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $9.36
Upside: +199.15%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $24.82
Upside: +24.92%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $13.08
Upside: +2,805.20%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.78
Upside: +166.85%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $29.04
Upside: +23.97%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $32.68
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $2.90
Upside: +1,175.86%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $170.00
Upside: -24.71%